RGNX241220C10000
- 0.40
- 0.000.00%
Regenxbio Newsroom
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
RBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)
Express News | Regenxbio Inc - to Offer and Sell Shares up to $150 Million
Express News | Regenxbio Inc - on Dec 9, Co Enters Sales Agreement With Leerink Partners
Apollo Global Management, Workday to Join S&P 500
Champion Homes to Replace Regenxbio in S&P 600 at Open on 12/23
Express News | S&P Dow Jones Indices: Terreno Realty Corp. and Champion Homes Inc. Will Replace Hudson Pacific Properties Inc. and Regenxbio Inc. in S&P Smallcap 600
REGENXBIO Price Target Cut to $36.00/Share From $40.00 by HC Wainwright & Co.
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $36
Buy Rating on RegenXBio Driven by Positive RGX-202 Trial Results and Strong Approval Prospects
Express News | Regenxbio Inc. : H.c. Wainwright Cuts Target Price to $36 From $40
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $50
REGENXBIO Price Target Maintained With a $52.00/Share by Chardan Capital
REGENXBIO Is Maintained at Buy by Chardan Capital
Regenxbio Eyes 2026 Filing for Duchenne Muscular Dystrophy Gene Therapy
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $25
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
Stifel Nicolaus Sticks to Its Buy Rating for RegenXBio (RGNX)
A Quick Look at Today's Ratings for Regenxbio(RGNX.US), With a Forecast Between $18 to $50
RegenXBio's RGX-202: Promising DMD Therapy With Best-in-Class Potential and Strategic BLA Plans